<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000331</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-11160-6</org_study_id>
    <secondary_id>R01DA011160</secondary_id>
    <secondary_id>R01-11160-6</secondary_id>
    <nct_id>NCT00000331</nct_id>
  </id_info>
  <brief_title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6</brief_title>
  <official_title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the abuse liability and examine the reinforcing
      effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy,
      non-drug dependent volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      not available at this time
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed withdrawal rating</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupil diameter</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug effect characteristics</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heroin Dependence</condition>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug to prevent heroine withdrawal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Drug</intervention_name>
    <arm_group_label>Test Drug</arm_group_label>
    <other_name>test drug o</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Drug</intervention_name>
    <arm_group_label>Placebo Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age,
        and have no prior history of drug or alcohol abuse or dependence. Subjects must have had
        some minimal experience with opioids (e.g. at least two prior exposures)

        Exclusion Criteria:

        Individuals with evidence of an active Diagnostic and Statistical Manual of Mental
        Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness,
        organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular
        disease) or pregnant female subjects are excluded from study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Amass, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 1999</study_first_submitted>
  <study_first_submitted_qc>September 20, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 1999</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heroin Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

